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Abstract 
BACKGROUND: Schizophrenia is a severe mental disorder that is multi-causative and multi-factor, generally 
affecting about 1% of the population. The elevation level of brain-derived neurotrophic factor (BDNF) offers 
several protections from other neurodegenerative processes that occur in schizophrenia since this deficit of 
neurotrophic factors can contribute to changes in brain structure and function that underlie the schizophrenia 
psychopathology. 
AIM: To analyse the correlation between BDNF serum levels and symptom severity by using the Positive and 
Negative Syndrome Scale (PANSS) instrument in Bataknese male patients with schizophrenia 
METHODS: This study was a correlative analytical study with a cross-sectional approach using the Positive and 
Negative Syndrome Scale (PANSS) instrument to assess symptom severity with 60 subjects of Bataknese male 
patients with chronic schizophrenia. Moreover, this research was conducted at the Psychiatric Hospital of Prof. Dr 
M. Ildrem Medan, Indonesia. BDNF serum was analysed with the Quantitative sandwich enzyme immunoassay 
technique by via Quantikine ELISA Human CXCL8/IL-8 HS. Also, the data analysis was performed through 
Spearman's correlative bivariate analytics using SPSS software. 
RESULTS: A negative correlation between the BDNF serum level and the negative scale PANSS score in men 
with schizophrenia (r = -0.820, p < 0.001) was found. Moreover, there is a negative correlation between BDNF 
serum levels and PANSS total scores in men with schizophrenia (r = -0.648, p < 0.001) 
CONCLUSION: BDNF serum level in Bataknese male patients with schizophrenia has a relationship that affects 
the severity of symptoms in schizophrenic patients, especially for negative symptoms. 
 
 
 
 
Introduction 
 
Schizophrenia is a common psychotic 
disorder, with a risk of around 1%. The most frequent 
initial onset of this disorder is the age of 15-30 years 
and is a chronic disease that disrupts patients and 
their families. Moreover, it has a major impact on 
society and economy [1]. Schizophrenia patients 
experience complex mental deterioration disorders. 
The mechanism that causes this disorder is still 
unclear, but some evidence shows that the cause is 
multi-causal and multi-factors. These factors include 
genetic, neuro-developmental, social [2], [3], [4], [5], 
[6] and immune factors [7]. On the other hand, 
schizophrenia is not a static mental disorder but a 
dynamic process that causes dysregulation of various 
pathways [8]. Other factors that are suspected of 
having a role in the presence of a degenerative 
central nervous system (neuro-degeneration) [9]. 
The aetiology and pathophysiology of 
schizophrenia have not been explained so far. Various 
changes in the central nervous system can cause 
clinical manifestations of the disease. 
Neurotransmitter deficits are considered as 
epiphenomena underlying the disorganisation of 
neurotropins [10]. Brain-Derived Neurotropic Factor 
(BDNF), a member of the neurotropic derivative, is 
often found in adult mammalian brains and plays an 
important role in the development, regeneration, 
survival, maintenance and function of neurons [11], 
[12]. During the development, BDNF plays an 
important role in maintaining proper axonal growth. 
BDNF is also essential for the development and 
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survival of dopaminergic, serotonergic, GABAergic, 
and cholinergic neurons. Also, there are significant 
roles in the pathophysiology of psychiatric diseases, 
including schizophrenia [13]. 
Furthermore, BDNF plays an important role in 
the mesolimbic dopaminergic system and regulates 
the expression of D3 dopamine receptors [14]. Finally, 
BDNF is produced by immune cells in response to 
neuroimmune and inflammatory response to protect 
the brain from any damage. Based on this evidence, 
BDNF turns into a potentially useful biomarker to 
study the inflammatory features of schizophrenia, 
which has a role in the persistent negative symptoms 
and cognitive features in schizophrenia [15]. This 
suggests that a relationship between BDNF properties 
with dopamine pathway in schizophrenia [16]. 
Some studies performed sub-categories of 
schizophrenia symptoms into 5 parts, positive 
symptoms, negative symptoms, cognitive symptoms, 
aggressive symptoms and depression/anxiety 
symptoms [1]. Negative symptoms of schizophrenia 
are characterised by the deficits in normal emotions 
and social functions that can be primary or secondary 
for the treatment of diseases or other manifestations. 
These symptoms are strongly associated with long-
term paralysis that tends to worsen over time and 
negatively affect the patient's quality life. Despite this 
burden, negative symptoms are more resistant to 
treatment compared to positive symptoms, and 
existing antipsychotics are not able to reduce the 
negative symptoms of schizophrenia [17]. In general, 
Indonesian population is determined to follow the 
paternalistic line (father/male), for example, the 
Javanese and Bataknese tribes. In this case, 
Bataknese male will give offspring who are also 
Bataknese. The total number of ethnic groups in 
Indonesia as a whole reaches more than 1,300 ethnic 
groups. In addition to the various types, the number or 
size of the population of each type of ethnic group is 
also very varied [18]. In this study, the subjects 
chosen were Bataknese. The author was interested in 
choosing the Bataknese because the majority of 
schizophrenia patients who were hospitalised in the 
psychiatric hospital, Prof. Dr M. Ildrem in North 
Sumatra is Batak tribe. 
To sum up, this study is aimed to investigate 
the relationship between BDNF serum levels and 
symptom severity measured using the PANSS 
instrument in Batak male patients with chronic 
schizophrenia. 
 
 
Methods 
 
This study performed a cross-sectional study 
design to evaluate the relationship of BDNF serum 
level as of symptoms severity as measured by 
PANSS in Bataknese male patients with 
schizophrenia. The total sample of this study was 60 
people, collected using the consecutive sampling 
method. Furthermore, this study has followed the 
Medical Ethics Committee of Universitas Sumatera 
Utara, Medan, Indonesia. 
Participants: A total of 60 subjects with 
schizophrenia were established by structured 
interviews using the MINI ICD-10, which was 
hospitalised at the Psychiatric Hospital of Prof. dr. M. 
Ildrem, Medan, Indonesia.  
Inclusion criteria: Age between 20-60 years, 
bataknese male, smoking, chronic schizophrenia 
patients for 2 years with stabilisation phase (PANSS 
60-80 score), understanding Indonesian language, 
willing to be a respondent and able to be interviewed.  
Exclusion Criteria: Having other mental 
disorders, suffered from neurologic diseases, history 
of alcohol use and other substances except for 
tobacco. 
Data collection was preceded by screening 
using inclusion and exclusion criteria. Individuals who 
met the inclusion criteria and exclusion criteria were 
asked for approval to take part in the study after 
obtaining informed consent. Then, the demographic 
data of the subject were filled PANSS score 
assessment on the research subject was performed. 
The next stage was as much as 5 ml of the subject’s 
blood samples were taken by laboratory officers who 
will then be examined in the laboratory to obtain the 
result of BDNF serum level. 
 
Measurement 
The severity was measured through the 
Positive and Negative Syndrome Scale (PANSS). It 
was developed in the late 1980s aimed at assessing 
clinical symptoms of schizophrenia. PANSS contains 
30 items in three subscales, seven items include 
positive symptoms (for example, delusions and 
hallucinations), seven items include negative 
symptoms (for example, social withdrawal, flat affect, 
lack of motivation), and 16 items include general 
psychopathology (for example, anxiety and 
depression). Assessment can be completed in 30 to 
40 minutes. The reliability is good, and the validity is 
very good [19]. In previous PANSS examination, the 
former of the researcher was trained with an 
interpreter, which then PANSS score will be 
conducted with a suitability test between the 
researcher and the interpreter. 
BDNF was assessed by taking 5 ml of the 
subject’s blood samples by laboratory personnel in the 
morning at around 8 am, which will then be examined 
in the laboratory to obtain the results of BDNF levels. 
BDNF serum levels were analysed with the 
Quantitative sandwich enzyme immunoassay 
technique by the use of Quantikine ELISA Human 
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CXCL8/IL-8 HS.  
The sample used was a human serum. The 
standard calibration range is 62.5-4000 pg / mL. The 
limit of detection is 20 pg / mL, and the dilution factor 
is 20 times. The results have been multiplied by a 
dilution factor. Measurements using the Microplate 
Reader Biorad model 680 instruments (Bio-rad 
Laboratories Inc., CA, USA) with the Microplate 
Manager version 5.2.1 software (Bio-rad Laboratories 
Inc., CA, USA). 
 
Data Analysis 
The normal distribution test was performed 
through the Kolgomorov-Smirnov test. Moreover, the 
analysis between BDNF serum levels and each 
PANSS score item was conducted using the 
Spearman's correlative bivariate analytic (N = 60, Zα 
5%, Zᵦ 20%) with SPSS 22 software (SPSS Inc, 
Chicago, Illinois, USA), and p < 0.05 was considered 
as statistically significant. 
 
 
Results 
 
A total of 60 research subjects were analysed. 
In Table 1, the demographic characteristics of the 
research subjects are described. The average age of 
the study subjects was 37.65 years with a standard 
deviation of 6.58 years.  
Table 1: The demographic characteristic of the research 
subject 
Variable Mean/f SD/% 
Age 37.650 6.581 
Educational Background 
Junior High school 
Senior High school 
Diploma  
 
17 
41 
2 
 
28.3% 
68.3% 
3.3% 
Marital Status 
Not married 
Married 
 
19 
41 
 
31.7% 
68.3% 
Smoking Level 
Current smokers 
Former smokers 
Never smokers 
 
31 
21 
8 
 
51.7% 
35.0% 
13.3% 
Relapse  3.417 0.497 
Body Mass Index 22.232 1.543 
Mean/f: Mean/Frequency; SD/%: Standard Deviation/Percentage. 
 
The highest level of education is a senior high 
school with 41 people (68.3%). Most subjects are 
married (68.3%) and 51.7% of samples are a current 
smoker. Furthermore, the mean of relapse was 3.417 
(SD = 0.497), and the average Body Mass Index is 
22.232 (SD = 1.543). 
Table 2: The BDNF serum level and PANSS score 
Variable Mean ± SD 
BDNF serum 
PANSS Positive score 
PANSS negative score 
Psychopathology general PANSS score  
Total PANSS score 
24.573 ± 4.035 
11.050 ± 2.118 
26.783 ± 3.923 
31.466 ± 3.202 
69.300 ± 6.181 
In Table 3, it can be seen that a negative 
correlation between BDNF level and PANSS scores is 
discovered. There was a strong and significant 
correlation between BDNF serum levels and negative 
PANSS scores (r = -0.820, p < 0.001) and between 
BDNF serum levels and PANSS total scores (r = -
0.664, p < 0.001). Moreover, a very weak correlation 
between BDNF serum level and positive PANSS 
score and PANSS score general psychopathology is 
recorded. 
Table 3: The correlation between BDNF and PANSS 
 PANSS Score Coefficient Correlation (r) p 
BDNF PANSS Positive score 
PANSS negative score 
Psychopathology general PANSS 
score 
Total PANSS score 
-0.155 
-0.820 
-0.140 
-0.648 
0.237 
< 0.001
* 
0.287 
< 0.001
* 
*Spearman correlation (p < 0.05). 
 
 
 
Discussion 
 
The main finding in this cross-sectional study 
was a negative correlation between BDNF serum 
levels and negative scale PANSS scores in 
Bataknese male patients with schizophrenia and a 
negative correlation between BDNF serum levels and 
PANSS total scores. This study is by Akyo et al., 
(2015) which concluded that there were negative 
correlations between BDNF peripheral measured 
levels and the symptomatology of schizophrenia. 
BDNF plays an important role in the development of 
the central nervous system. It has an impact on the 
serotonergic signalling, glial cells, hippocampus 
neurons and the brain cortex. Moreover, BDNF, in 
contrast to other neurotrophins, is secreted in 
response to neuron excitation and releasing dopamine 
and glutamate from the hippocampal cells. BDNF 
expression in the frontal cortex can be regulated via 
dopaminergic receptors [20,21]. Koeva (2014) 
discovered that changes in the neurotrophic factor 
system were one of the factors considered in the 
pathological cascade of schizophrenic psychosis. The 
decreased BDNF serum levels show a potential deficit 
in the release of neurotrophic factors in patients with 
schizophrenia. The results of this study support the 
view that BDNF is related to schizophrenia [10]. 
Furthermore, this study is also by the study of 
Sasha (2018), found that the levels of BDNF serum 
were associated with negative symptoms in older 
adults with schizophrenia. She found that the higher 
BDNF serum level and greater severity of negative 
symptom items [13]. Recently, Niitsu et al. (2014) 
investigated BDNF levels in patients with 
schizophrenia. They reported that the serum was 
mature and had a positive correlation between BDNF 
serum levels and negative symptoms. They concluded 
that the mature BDNF might not be a good candidate 
as a biomarker in schizophrenia [22]. 
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According to Zhang et al., (2010), an increase 
in BDNF levels protects the neurodegenerative 
processes that occur in schizophrenia, since this 
deficit of neurotrophic factors can contribute to 
changes in brain structure and function underlying the 
psychopathology of schizophrenia [11]. The nervous 
development of abnormalities and dopamine 
dysregulation systems have been implicated in the 
pathophysiology of schizophrenia. Therefore, BDNF 
can be a marker of abnormal nerve development and 
neurotransmission in schizophrenia [23]. The BDNF 
serum levels are widely measured in numerous 
psychiatric disorders, and the use of BDNF plays a 
role in the treatment of many psychiatric disorders 
[20]. 
In contrast to Fernandez et al. (2015), 
peripheral BDNF levels in serum and plasma were 
slightly reduced in Schizophrenia compared to 
controls. In particular, this decline is emphasised by 
the duration of the disease. However, the rate of 
decrease in peripheral BDNF levels did not correlate 
with the severity of positive and negative symptoms. 
In plasma, but not serum, peripheral BDNF levels 
consistently increase after the antipsychotic treatment 
regardless of the patient's response to treatment [24]. 
For BDNF itself, there are many factors that 
contribute to influence, such as gender, smoking 
habit, body mass index, etc. In this study, the 
recruited subjects were male patients, where previous 
studies have stated that gender affects serum BDNF 
levels. Estrogens have multiple functions in the brain. 
Pluchino et al. (2013) showed that estrogen could 
regulate the expression of BDNF via the estrogen 
response element on the BDNF gene. Another group 
also indicated that BDNF mediated the effects of 
testosterone on neuronal survival [25]. In the baseline 
data, it is found that the most current smokers are 31 
people (51.7%) as in the study of Zhang and 
colleagues found a significant association between 
BDNF levels and negative symptoms of schizophrenia 
with a further link to nicotine. Because the negative 
symptoms of schizophrenia are associated with 
hypoactivity of the dopaminergic system, smoking can 
reduce negative symptoms by increasing dopamine in 
the nucleus accumbency. Also, BDNF increases the 
release of dopamine in the mesolimbic dopamine 
system and induces dopamine-related behaviours 
[11]. 
For Body Mass Index, the subjects selected 
were in normal-weight categorisation, considering 
previous studies by Lommatzsch et al., (2005) shown 
that plasma BDNF levels in people health decrease 
significantly with weight gain [26]. Araya et al., (2008) 
also emphasized the relationship between weight and 
plasma BDNF levels in overweight and obese people 
who had gone on a diet, where BDNF levels 
increased after 3 months on a diet [27]. 
This study has decided that Batak tribes were 
chosen. Whether there is a connection between the 
Bataknese male patients and BDNF serum levels, it 
still needs further and deeper research. Previous 
research stated that there were 2 types of sequences 
of Batak ethnics especially in BP 113-116 were 
observed. Also, it was expected that Batak ethnicity 
had a tradition to keep their purity by marrying their 
relative would show a similar sequence. However, no 
similarity was found. The reason of these phenomena 
could be resulted by some Bataknese man married 
with other race, but they adopted their wife or 
husband into ethnic Batak by adding a Batak's 
surname. Interestingly, batak ethnic with ATCG 
sequences were categorized to have higher risk for 
having schizophrenia [28]. 
In this study, a strong and significant 
correlation has been discovered. There is a negative 
correlation between BDNF serum level and negative 
PANSS score in Batak male schizophrenia patients (r 
= -0.820, p < 0.001) in the sense that the higher the 
severity of negative symptoms in Schizophrenic 
patients, the lower serum BDNF levels. In this study 
there was also a negative correlation between BDNF 
serum levels and PANSS total score in Bataknese 
male patients with schizophrenia (r = -0,648, p < 
0.001). 
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